Can We Really Use ss-Lactam/ss-Lactam Inhibitor Combinations for the Treatment of Infections Caused by Extended-Spectrum ss-Lactamase-Producing Bacteria?

Multicenter Evaluation of a New DNA Microarray for Rapid Detection of Clinically RelevantblaGenes from β-Lactam-Resistant Gram-Negative Bacteria

(2011) Pierre Bogaerts et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Activities of NXL104 Combinations with Ceftazidime and Aztreonam against Carbapenemase-ProducingEnterobacteriaceae

(2010) David M. Livermore et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Three Decades of  -Lactamase Inhibitors

(2010) S. M. Drawz et al.   CLINICAL MICROBIOLOGY REVIEWS

AmpC β-lactamases in Escherichia coli: emergence of CMY-2–producing virulent phylogroup D isolates belonging mainly to STs 57, 115, 354, 393, and 420, and phylogroup B2 isolates belonging to the international clone O25b–ST131

(2010) Jesús Oteo et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Absence of Association between Use of Ertapenem and Change in Antipseudomonal Carbapenem Susceptibility Rates in 25 Hospitals

(2010) Kathryn J. Eagye et al.   INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

Diversity of Escherichia coli Strains Producing Extended-Spectrum  -Lactamases in Spain: Second Nationwide Study

(2010) M. A. Diaz et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Clinical Features and Molecular Epidemiology of CMY‐Type β‐Lactamase–ProducingEscherichia coli

(2009) Hanna E. Sidjabat et al.   CLINICAL INFECTIOUS DISEASES

Antimicrobial susceptibility of well-characterised multiresistant CTX-M-producing Escherichia coli: failure of automated systems to detect resistance to piperacillin/tazobactam

(2008) Johann D.D. Pitout et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS